U.S. Entertainment Stock News

NasdaqGM:MAZE
NasdaqGM:MAZEPharmaceuticals

Maze Therapeutics (MAZE) Q1 Loss Of US$24.2 Million Reinforces Bearish Earnings Narratives

Maze Therapeutics (MAZE) opened Q1 2026 with revenue of US$20 million and a basic EPS loss of US$0.45, alongside a net income loss of US$24.21 million, setting an earnings-season tone that is still firmly focused on managing losses. Over the past few quarters the company has gone from zero reported revenue in each quarter of 2025 to US$20 million in Q1 2026. Quarterly basic EPS has ranged from a loss of US$1.15 in Q1 2025 to a loss of US$0.45 in the latest period, putting the spotlight on how...
NYSE:REZI
NYSE:REZIBuilding

Resideo Sets Leadership For ADI Spin Off As Valuation Draws Attention

Resideo Technologies (NYSE:REZI) announced new leadership appointments for both Resideo and its planned spin off, ADI Global Distribution. The company outlined executive and board roles that will govern each business after the separation is complete. The spin off of ADI Global Distribution remains on track for completion between the third and fourth quarters of 2026. Resideo, which focuses on comfort, security and related products and services for homes and businesses, is preparing to...
NasdaqGS:NCMI
NasdaqGS:NCMIMedia

National CineMedia (NCMI) Q1 Loss Reopens Debate Around Earnings Stability Narratives

Q1 2026 earnings snapshot National CineMedia (NCMI) has reported Q1 2026 revenue of US$34 million with a basic EPS loss of US$0.31, while trailing twelve month figures show revenue of US$242.3 million and a basic EPS loss of US$0.09. Over recent quarters, the company has seen quarterly revenue range from US$34 million to US$93.2 million, with basic EPS moving between a loss of US$0.32 and a profit of US$0.31. This sets up a mixed picture on earnings quality and operating leverage. For...
NYSE:BEN
NYSE:BENCapital Markets

Franklin Resources Explores Onchain And Private Markets As Shares Outpace Targets

Franklin Resources (NYSE:BEN), through Franklin Templeton, has entered an onchain collaboration with Payward, the operator of Kraken, to develop tokenized, actively managed investments for institutional clients. The company has also launched Private Markets Model Portfolios with Corastone, aiming to give financial advisors more efficient access to diversified private market investments. These product moves come as Franklin Resources trades around $32.04, with the stock up 2.8% over the past...
NYSE:IFF
NYSE:IFFChemicals

IFF Vanilla Hub In Madagascar Ties Origin Sourcing To Undervalued Stock Narrative

IFF (NYSE:IFF) has opened a Vanilla Innovation Center in Madagascar, a key origin for natural vanilla. The facility is intended to focus on origin-based product development, sustainability, and local supply chain support. The center links Madagascar vanilla production with IFF’s broader global vanilla network for food, beverage, and fragrance customers. For investors watching NYSE:IFF, this move sits at the intersection of flavor, fragrance, and consumer demand for traceable, natural...
NasdaqGS:GTLB
NasdaqGS:GTLBSoftware

GitLab Restructuring For Agentic AI Era Tests Execution And Valuation

GitLab (NasdaqGS:GTLB) has announced a major global restructuring and workforce reduction aimed at repositioning the company for what it calls the agentic AI era. The plan includes country exits, a flatter management structure, and a shift to smaller autonomous teams focused on AI driven software development. GitLab intends to reinvest cost savings from the restructuring into AI infrastructure and an AI centric engineering operating model referred to internally as Act 2. The company has...
NasdaqGS:CCCC
NasdaqGS:CCCCBiotechs

C4 Therapeutics (CCCC) Q1 Loss Of US$25.1 Million Reinforces Profitability Concerns

C4 Therapeutics (CCCC) has opened 2026 with Q1 revenue of US$6.2 million and a basic EPS loss of US$0.20, alongside a trailing twelve month revenue base of US$34.9 million and a net loss of US$103.8 million, setting a clear tone for how the market will read the latest update. Over recent quarters the company has seen revenue move between US$5.2 million in Q4 2024 and US$11.2 million in Q3 2025, while quarterly basic EPS has ranged from a loss of US$0.18 to a loss of US$0.49. This print keeps...
NYSEAM:EPM
NYSEAM:EPMOil and Gas

Evolution Petroleum (EPM) Reports US$8.9 Million Q3 Loss Challenging Bullish Earnings Narratives

Evolution Petroleum (EPM) has just posted a soft Q3 2026, with total revenue of US$20.2 million and a basic EPS loss of US$0.26 alongside a net loss of US$8.9 million, setting a cautious tone for the quarter. The company has seen quarterly revenue move in a tight band between US$20.2 million and US$22.6 million over the past six reported periods, while EPS has swung between a profit of US$0.10 and a loss of US$0.26, leaving investors focused on how consistently the business can translate its...
NasdaqGS:MIDD
NasdaqGS:MIDDMachinery

Middleby Spin Off Of Midera Reshapes Growth Story And Valuation

Middleby is spinning off its Food Processing segment as Midera Food Processing Inc., creating two independent public companies. The newly named Midera will have its own management team, strategic roadmap, and three year financial guidance. The spin off includes a set timetable, with Midera common stock planned to begin trading on a specified future date. For investors following NasdaqGS:MIDD, this move reshapes how you think about the stock. Middleby shares recently closed at $147.45, with...
NYSE:ARW
NYSE:ARWElectronic

Arrow Electronics Remote Lab Service Aims To Deepen Engineering Engagement

Arrow Electronics (NYSE:ARW) has introduced Digital Test Drive, a cloud-based remote engineering service. The service allows users to access and test hardware remotely through secure connections to Arrow’s engineering labs. Digital Test Drive is intended to reduce friction from kit availability, shipping logistics, and on-site setup. Arrow Electronics (NYSE:ARW) operates as a global distributor and solutions provider for electronic components and enterprise computing products. With Digital...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives

Catalyst Pharmaceuticals (CPRX) opened Q1 2026 with total revenue of US$149.4 million and basic EPS of US$0.52, setting a clear marker for how the year is starting. The company has seen quarterly revenue range from US$141.4 million in Q1 2025 to US$152.6 million in Q4 2025, while basic EPS moved between US$0.43 and US$0.47 over that period, giving you a solid view of how the top and bottom line have been tracking into the latest print. With a trailing net profit margin of 37.1% and earnings...
NasdaqGS:TTAN
NasdaqGS:TTANSoftware

Is It Time To Reassess ServiceTitan (TTAN) After A 53% One Year Share Price Fall?

Wondering whether ServiceTitan at around US$57.50 is an opportunity or a value trap? This article breaks down what the current price could mean for you. The stock has been volatile recently, falling around 10% over the past week, rising about 4% over the past month, yet still down around 43.4% year to date and 53.3% over the past year. Recent coverage has focused on ServiceTitan as a software player in the trades and field services space, with attention on how its growth story lines up with...
NYSE:LAD
NYSE:LADSpecialty Retail

Lithia Motors Resets Dealership Model As Valuation Discount Draws Investor Focus

Lithia Motors (NYSE:LAD) has announced a broad reorganization of its dealership operations and management structure. The company plans to centralize dealership management, merge sales and F&I roles, and test remote work options for certain staff. Lithia is also piloting a new digital dealer management system aimed at tightening coordination across locations. These changes represent a company wide operational reset focused on efficiency and long term competitiveness. Lithia Motors is one of...
NYSE:ASIC
NYSE:ASICInsurance

Undiscovered Gems in the US Market for May 2026

The United States market has shown robust performance, with a 1.5% increase over the last week and a remarkable 26% climb in the past year, supported by expected annual earnings growth of 17%. In such a thriving environment, identifying stocks that are not only poised for growth but also remain under the radar can offer unique opportunities for investors seeking to diversify their portfolios.
NasdaqCM:REKR
NasdaqCM:REKRSoftware

Rekor Systems (REKR) Cash Runway Strain Reinforces Bearish Profitability Narrative

Rekor Systems (REKR) opened 2026 with Q1 results that sit against a trailing 12 month picture of US$48.45 million in revenue, a loss of US$31.46 million and basic EPS of a US$0.26 loss, with the stock trading around US$0.81. Over recent quarters the company has reported quarterly revenue ranging from US$9.20 million to US$14.19 million, while basic EPS has moved between a loss of US$0.10 and a loss of US$0.03. This gives investors a view of a business still carrying meaningful losses. The...
NasdaqGM:CAMT
NasdaqGM:CAMTSemiconductor

Camtek’s AI Orders And Acquisition Drive Lofty Growth Expectations And Valuation

Camtek (NasdaqGM:CAMT) reports exceptionally strong incoming orders tied to advanced semiconductor packaging and AI-driven inspection. The company highlights recent AI-focused deals, including its acquisition of Visual Layer, as a key part of its technology roadmap. Management signals an expectation for more than 25% revenue growth in the second half of 2026, pointing to a step change in demand. For investors tracking NasdaqGM:CAMT, the fresh orders and AI-focused investments add a new...
NasdaqGM:CHRS
NasdaqGM:CHRSBiotechs

Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives

Coherus Oncology (CHRS) opened Q1 2026 with total revenue of US$12.3 million and a basic EPS loss of US$0.27, presenting a clear picture of a business still in investment mode. Over recent quarters the company reported revenue of US$7.7 million in Q4 2024, US$7.6 million in Q1 2025, US$10.3 million in Q2 2025, US$12.7 million in Q4 2025, and US$12.3 million in the latest quarter. Over the same period, basic EPS losses moved from US$0.40 in Q4 2024 to US$0.41 in Q1 2025, then around US$0.38...
NYSE:ESNT
NYSE:ESNTDiversified Financial

Is It Time To Reassess Essent Group (ESNT) After Steady Returns And Valuation Gap

Wondering if Essent Group at US$60.87 is still a good deal or already pricing in the story? This article breaks down what the current share price might be implying about value. The stock has been relatively steady, with returns of 1.2% over the past week, 0.6% over the past month, a decline of 5.9% year to date, and a 4.6% return over the last year. The 3 year and 5 year returns sit at 48.5% and 40.5% respectively. Recent coverage around Essent Group has focused on its position within the...